Sonoma Biotherapeutics
Melita Dvorak-Ewell has a strong background in program and portfolio management in the biopharmaceutical industry. Melita has worked at various companies including Sonoma Biotherapeutics, Audentes Therapeutics, Ultragenyx Pharmaceutical Inc., KnowledgePoint360 Group, and BioMarin Pharmaceutical Inc. Prior to their industry positions, Melita was involved in postdoctoral research at UCSF.
This person is not in any offices
Sonoma Biotherapeutics
1 followers
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.